Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 44 min ago
PreprintCC BY-NC-NDmedRxiv

Longitudinal Plasma Proteomics Distinguishes Primary Immune Tolerance from Chronic Graft-versus-Host Disease After Pediatric allo-HSCT

  1. 1University of Helsinki

Abstract

Chronic graft-versus-host disease (cGvHD) remains a major cause of morbidity after pediatric allogeneic hematopoietic stem cell transplantation (HSCT), but the early plasma molecular features associated with primary immune tolerance (PIT) versus cGvHD are incompletely understood. We performed longitudinal LC-MS plasma proteomics in 32 pediatric allo-HSCT recipients sampled at Months 1, 3, 6, 9, and 12 after transplantation, quantifying 4,702 proteins. Across timepoint-specific differential-abundance analyses, Month 3 showed the strongest observed PIT-cGvHD proteomic separation and was selected for deeper exploratory characterization. At Month 3, eight proteins were higher in PIT at BH-FDR <0.05, including the 19S proteasome ATPases PSMC1, PSMC3 and PSMC5, the chaperonin subunit CCT3, the ubiquitin-conjugating enzyme UBE2O, and APEH, RAN and NME1, pointing to differences in protein degradation and folding pathways. Time-resolved pathway analysis showed PIT-associated immune, immunoglobulin, and proteostasis programs at distinct post-transplant intervals, whereas Month-3 cGvHD-associated profiles were enriched for platelet activation, cell adhesion, transmembrane transport, and metabolic processes. Outcome-blinded clustering of the 500 most temporally variable proteins resolved three descriptive trajectory patterns: a transient Month-3 peak, a Month-3 nadir with late recovery, and an early-high/late-decline pattern. The distribution of Month-3 PIT and cGvHD protein effects differed across outcome-blinded trajectory clusters, providing an internally consistent temporal framework for the Month-3 signal. These exploratory findings nominate Month 3 as a potentially informative interval of molecular divergence after pediatric allo-HSCT and identify pathway-level features of PIT and cGvHD for prospective validation.

Related

  1. Machine learning analysis of cilia driven particle transport distinguishes primary ciliary dyskinesia from normal cilia
    Nicholas Hadas, Huihui Xu, Shambhawee Neupane +5
    Communications BiologyPeer-reviewedCC BY 4.0Full textGeneral medicineCrossref
  2. Longitudinal Drain-Fluid Proteomics Reveals Procedure-Specific Signatures of Postoperative Leakage after Pancreatic and Colorectal Surgery
    A. Jessernig, V. M. Agboola, S. Pfammatter +4
    medRxivPreprintAll rights reservedFull textSurgery & anaesthesiamedRxiv
  3. Plasma proteomics for prognostic stratification in newly diagnosed primary central nervous system lymphoma
    Tamara Künzle, Dora Herzi, Clara Boer Wigman +20
    Neuro-OncologyPeer-reviewedPublisher termsFull textNeurologyPMC
  4. Paired longitudinal tear proteomics reveals persistent ocular surface dysregulation after teprotumumab therapy in thyroid eye disease
    Gabriel Velez, Gia-Han Ngo, Daniel Young +4
    Communications MedicinePeer-reviewedCC BYFull text1 citedEpidemiology & public healthDOAJ
  5. Maternal bonding difficulties and postpartum depression in pediatric clinical practice: a longitudinal study in a Japanese cohort
    Tomomi Yasaka, Takashi X. Fujisawa, Akemi Tomoda
    Frontiers in psychiatryPeer-reviewedCC BYFull textPsychiatry & mental healthEurope PMC
BibTeX
@misc{kim2026longitudinal,
  title = {{Longitudinal Plasma Proteomics Distinguishes Primary Immune Tolerance from Chronic Graft-versus-Host Disease After Pediatric allo-HSCT}},
  author = {D. Kim and Y. Jing and E. Aarimaa and E. Jarvinen and H. Lang and A. Alexandersson and S. Ryhanen and M. Koskenvuo and M. Varjosalo and E. Kekalainen},
  howpublished = {medRxiv},
  year = {2026},
  month = oct,
  doi = {10.64898/2026.10.26.26365891},
  url = {https://www.medrxiv.org/content/10.64898/2026.10.26.26365891v1},
  note = {CC BY-NC-ND},
}
RIS
TY  - UNPB
TI  - Longitudinal Plasma Proteomics Distinguishes Primary Immune Tolerance from Chronic Graft-versus-Host Disease After Pediatric allo-HSCT
AU  - D. Kim
AU  - Y. Jing
AU  - E. Aarimaa
AU  - E. Jarvinen
AU  - H. Lang
AU  - A. Alexandersson
AU  - S. Ryhanen
AU  - M. Koskenvuo
AU  - M. Varjosalo
AU  - E. Kekalainen
PY  - 2026
DA  - 2026/10/26
PB  - medRxiv
DO  - 10.64898/2026.10.26.26365891
UR  - https://www.medrxiv.org/content/10.64898/2026.10.26.26365891v1
AB  - Chronic graft-versus-host disease (cGvHD) remains a major cause of morbidity after pediatric allogeneic hematopoietic stem cell transplantation (HSCT), but the early plasma molecular features associated with primary immune tolerance (PIT) versus cGvHD are incompletely understood. We performed longitudinal LC-MS plasma proteomics in 32 pediatric allo-HSCT recipients sampled at Months 1, 3, 6, 9, and 12 after transplantation, quantifying 4,702 proteins. Across timepoint-specific differential-abundance analyses, Month 3 showed the strongest observed PIT-cGvHD proteomic separation and was selected for deeper exploratory characterization. At Month 3, eight proteins were higher in PIT at BH-FDR <0.05, including the 19S proteasome ATPases PSMC1, PSMC3 and PSMC5, the chaperonin subunit CCT3, the ubiquitin-conjugating enzyme UBE2O, and APEH, RAN and NME1, pointing to differences in protein degradation and folding pathways. Time-resolved pathway analysis showed PIT-associated immune, immunoglobulin, and proteostasis programs at distinct post-transplant intervals, whereas Month-3 cGvHD-associated profiles were enriched for platelet activation, cell adhesion, transmembrane transport, and metabolic processes. Outcome-blinded clustering of the 500 most temporally variable proteins resolved three descriptive trajectory patterns: a transient Month-3 peak, a Month-3 nadir with late recovery, and an early-high/late-decline pattern. The distribution of Month-3 PIT and cGvHD protein effects differed across outcome-blinded trajectory clusters, providing an internally consistent temporal framework for the Month-3 signal. These exploratory findings nominate Month 3 as a potentially informative interval of molecular divergence after pediatric allo-HSCT and identify pathway-level features of PIT and cGvHD for prospective validation.
ER  -